RHBC
GILD icon

R.H. Bluestein & Co’s Gilead Sciences GILD Stock Holding History

R.H. Bluestein & Co’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$211K Sell
3,415
-700
-17% -$44.1K 0.01% 318
2022
Q2 		$254K Hold
4,115
– – 0.02% 292
2022
Q1 		$245K Hold
4,115
– – 0.01% 338
2021
Q4 		$299K Hold
4,115
– – 0.01% 319
2021
Q3 		$287K Buy
4,115
+700
+20% +$49.2K 0.01% 331
2021
Q2 		$235K Hold
3,415
– – 0.01% 384
2021
Q1 		$221K Sell
3,415
-305
-8% -$19.7K 0.01% 380
2020
Q4 		$217K Sell
3,720
-2,916
-44% -$176K 0.01% 358
2020
Q3 		$419K Sell
6,636
-167,164
-96% -$11.6M 0.02% 186
2020
Q2 		$13.4M Buy
173,800
+169,081
+3,583% +$13M 0.75% 43
2020
Q1 		$353K Buy
+4,719
New +$326K 0.03% 153
2018
Q4 		– Sell
-2,664
Closed -$206K – 297
2018
Q3 		$206K Buy
+2,664
New +$201K 0.01% 304
2017
Q4 		– Sell
-2,564
Closed -$208K – 324
2017
Q3 		$208K Buy
+2,564
New +$196K 0.01% 303
2017
Q1 		– Sell
-3,665
Closed -$262K – 331
2016
Q4 		$262K Buy
3,665
+45
+1% +$3.35K 0.02% 240
2016
Q3 		$286K Sell
3,620
-345
-9% -$28K 0.02% 213
2016
Q2 		$331K Sell
3,965
-260,472
-99% -$23.1M 0.03% 166
2016
Q1 		$24.3M Sell
264,437
-52,739
-17% -$4.76M 1.75% 25
2015
Q4 		$32.1M Buy
317,176
+20,163
+7% +$2.1M 2.01% 24
2015
Q3 		$29.2M Buy
297,013
+4,655
+2% +$517K 2.07% 21
2015
Q2 		$34.2M Buy
292,358
+29,022
+11% +$3.17M 2.08% 21
2015
Q1 		$25.8M Buy
263,336
+32,652
+14% +$3.32M 1.56% 32
2014
Q4 		$21.7M Sell
230,684
-17,342
-7% -$1.79M 1.36% 33
2014
Q3 		$26.4M Sell
248,026
-2,148
-0.9% -$210K 1.65% 29
2014
Q2 		$20.7M Buy
250,174
+34,664
+16% +$2.7M 1.23% 39
2014
Q1 		$15.3M Buy
215,510
+16,861
+8% +$1.32M 1.01% 41
2013
Q4 		$14.9M Buy
198,649
+171,315
+627% +$11.9M 0.94% 44
2013
Q3 		$1.72M Buy
27,334
+16,960
+163% +$1.01M 0.12% 72
2013
Q2 		$532K Buy
+10,374
New +$541K 0.05% 164

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

R.H. Bluestein & Co's GILD Position: Q3 2022 in Review

R.H. Bluestein & Co reduced its Gilead Sciences (GILD) stake by 17% in Q3 2022, selling an estimated $44.1K and leaving 3,415 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #318.

R.H. Bluestein & Co first reported a position in GILD in Q2 2013 and has held it in 28 quarters since. The position peaked at $34.2M in Q2 2015. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • R.H. Bluestein & Co held 3,415 shares of Gilead Sciences worth $211K as of Q3 2022.
  • R.H. Bluestein & Co sold 700 Gilead Sciences shares in Q3 2022, an estimated $44.1K.
  • Gilead Sciences made up 0.01% of R.H. Bluestein & Co's portfolio in Q3 2022, its #318 holding.
  • R.H. Bluestein & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 28 quarters since.
  • R.H. Bluestein & Co's Gilead Sciences position peaked at $34.2M in Q2 2015.
  • 1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.